News & IIVS Activities

IIVS e-News – October 2020

September 28, 2020

IIVS is pleased to announce that Allison Hilberer will participate in the OECD Test Guidelines Programme Expert Groups (OECD TG EG) for eye and skin irritation, phototoxicity and skin sensitization. Allison is a Toxicologist II and Study Director at IIVS where she oversees the conduct of in vitrostudies in these areas. Allison has also been involved in many validation ...

IIVS, RIFM and Shiseido Partner to Transfer Non-animal Photosafety Tests

July 14, 2020

IIVS, RIFM and Shiseido Partner to Transfer Non-animal Photosafety Tests

The Institute for In Vitro Sciences (IIVS) has entered into an agreement with Shiseido and the Research Institute for Fragrance Materials (RIFM) to support the technology transfer of non-animal tests for photosafety testing. The program aims to build upon IIVS’ current photosafety tiered testing program, which ...

Webinar : Use of Non-animal Skin Sensitization Methods

June 3, 2020

A recorded webinar on the "Use of Non-animal Skin Sensitization Methods" by IIVS’s Hans Raabe and US EPA's Gino Scarano and James Cox is now available for viewing at https://www.piscltd.org.uk/nam-webinars/. The webinar reviews the status of Non-Animal methods acceptance of skin sensitization testing ...

Services and Tools for COVID-19 Drug Development

May 21, 2020

IIVS provides robust test systems and assays to detect the adverse effects of diverse materials, including pharmaceuticals targeting COVID-19. The IIVS Respiratory Toxicology Program offers testing services using cutting edge 3D pulmonary models - in addition to human 2D primary cells and lines - such as reconstructed human airways and human precision-cut human lung slices (hPCLS) that contain ...

Respiratory Toxicology for Pharmaceutical Development

May 6, 2020

The Institute for In Vitro Sciences (IIVS) provides robust test systems and assays to detect the adverse effects of diverse materials, including pharmaceuticals targeting COVID-19. The IIVS Respiratory Toxicology Program offers testing services using cutting edge 3D pulmonary models - in addition to human 2D primary cells and lines - such as reconstructed human airways and precision-cut human lung...

FDA Releases New Guidance Recommending Alternatives to LLNA

April 22, 2020

FDA releases new guidance recommending the performance of alternative test methodologies in lieu of the murine-based Local Lymph Node Assay (LLNA) to assess skin sensitization potential for topically-applied drug products. This information can be found at 

Phototox and BCOP Russian Translations

February 25, 2020

IIVS, in collaboration with EPAA, is pleased to announce that our training videos for eye irritation and phototoxicity are now available with Russian subtitles. To view subtitled versions in different languages including Chinese, Portuguese and Spanish, please visit our YouTube channel. https://youtu.be/aVLiA3IkAgs https://youtu.be/DISE5yNYZck...

2020 SOT Enhancement of Animal Welfare Award Announced

January 23, 2020

IIVS offers our congratulations to Kristie Sullivan, Vice President for Research Policy with the Physicians Committee for Responsible Medicine, who has been awarded the

PETA Science Group Donates $50,000 in Equipment to IIVS

October 11, 2019

Gaithersburg, Md. — Animals don't have to suffer for your cosmetics, cleaners, pesticides, or drugs. The PETA International Science Consortium Ltd. is donating $50,000 in equipment to the Institute for In Vitro Sciences (IIVS), a nonprofit laboratory in Gaithersburg that conducts and develops animal-free test methods. IIVS will use the VITROCELL® Cloud inhalation exposure system — instead of ...

US EPA Commits to Dramatically Reduce Animal Testing

September 13, 2019

The US EPA has committed to dramatically reducing animal testing with a commitment for total elimination by the year 2035. IIVS is proud to have played a part in the move to reduce animal testing, starting with the successful development, and acceptance, of the non-animal eye-irritation defined approach, which was developed by an industry and regulatory consortium led by IIVS' CEO Rodger D. ...